Correlation Between Centessa Pharmaceuticals and Molecular Partners
Can any of the company-specific risk be diversified away by investing in both Centessa Pharmaceuticals and Molecular Partners at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Centessa Pharmaceuticals and Molecular Partners into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Centessa Pharmaceuticals PLC and Molecular Partners AG, you can compare the effects of market volatilities on Centessa Pharmaceuticals and Molecular Partners and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Centessa Pharmaceuticals with a short position of Molecular Partners. Check out your portfolio center. Please also check ongoing floating volatility patterns of Centessa Pharmaceuticals and Molecular Partners.
Diversification Opportunities for Centessa Pharmaceuticals and Molecular Partners
-0.4 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Centessa and Molecular is -0.4. Overlapping area represents the amount of risk that can be diversified away by holding Centessa Pharmaceuticals PLC and Molecular Partners AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Molecular Partners and Centessa Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Centessa Pharmaceuticals PLC are associated (or correlated) with Molecular Partners. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Molecular Partners has no effect on the direction of Centessa Pharmaceuticals i.e., Centessa Pharmaceuticals and Molecular Partners go up and down completely randomly.
Pair Corralation between Centessa Pharmaceuticals and Molecular Partners
Given the investment horizon of 90 days Centessa Pharmaceuticals PLC is expected to generate 0.61 times more return on investment than Molecular Partners. However, Centessa Pharmaceuticals PLC is 1.65 times less risky than Molecular Partners. It trades about 0.15 of its potential returns per unit of risk. Molecular Partners AG is currently generating about -0.07 per unit of risk. If you would invest 1,551 in Centessa Pharmaceuticals PLC on August 29, 2024 and sell it today you would earn a total of 179.00 from holding Centessa Pharmaceuticals PLC or generate 11.54% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Centessa Pharmaceuticals PLC vs. Molecular Partners AG
Performance |
| Timeline |
| Centessa Pharmaceuticals |
| Molecular Partners |
Centessa Pharmaceuticals and Molecular Partners Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Centessa Pharmaceuticals and Molecular Partners
The main advantage of trading using opposite Centessa Pharmaceuticals and Molecular Partners positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Centessa Pharmaceuticals position performs unexpectedly, Molecular Partners can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will offset losses from the drop in Molecular Partners' long position.The idea behind Centessa Pharmaceuticals PLC and Molecular Partners AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
| Molecular Partners vs. Mineralys Therapeutics, Common | Molecular Partners vs. AN2 Therapeutics | Molecular Partners vs. Pharvaris BV | Molecular Partners vs. PepGen |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Complementary Tools
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |